Boule Diagnostics AB 2024 AR2
The report outlines Boule Diagnostics AB's strategic transformation in 2024, including the decision to divest its Russian manufacturing operations and the closure of the BM950 5-part analyzer development project, which led to significant asset write-downs. Despite these challenges, the company achieved net sales of SEK 558 million with an improved gross margin of 45.2% due to production efficiencies. Boule also expanded its local partnerships, notably recording its first instrument license revenue in India with Q-line. Additionally, the company launched a new Quality Policy and integrated a "Maverick Culture" to drive operational excellence and employee engagement.
Company: Boule Diagnostics AB
Sector: Health Care
Country: Sweden
Year: 2024
Type: AR2
Pages: 86
Back to company
Boule Diagnostics AB
Annual Report
The report outlines Boule Diagnostics AB's strategic transformation in 2024, including the decision to divest its Russian manufacturing operations and the closure of the BM950 5-part analyzer development project, which led to significant asset write-downs. Despite these challenges, the company achieved net sales of SEK 558 million with an improved gross margin of 45.2% due to production efficiencies. Boule also expanded its local partnerships, notably recording its first instrument license revenue in India with Q-line. Additionally, the company launched a new Quality Policy and integrated a "Maverick Culture" to drive operational excellence and employee engagement.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees